BACKGROUND: Patients with advanced soft tissue sarcomas (STS) have limited therapeutic options. Sorafenib (BAY 43-9006) is a multitargeted tyrosine kinase inhibitor of raf, vascular endothelial growth factor receptors 1 (VEGFR1) through 3, platelet-derived growth factor B, fms-like tyrosine kinase 3, and c-kit, and some of these may be relevant in STS. METHODS: The authors tested sorafenib at a dose of 400 mg twice daily in patients with advanced vascular sarcoma (VS), high-grade liposarcomas, and leiomyosarcomas who had received 0 or 1 previous regimens for advanced disease. RESULTS: Fifty-one patients were accrued to the study, and 37 were evaluable for toxicity and response. There were no unexpected side effects and no confirmed responses. The median progression-free survival was 3 months, and the median overall survival was 17 months. Six of 8 patients in the VS cohort had prolonged clinical benefit (stable disease or better), resulting in a median progression-free survival of 5 months compared with 2 to 3 months for the patients who had liposarcoma and leiomyosarcomas. CONCLUSIONS: Sorafenib at the dose and schedule studied did not result in any responses in the VS, liposarcoma, or leiomyosarcoma cohort according to Response Evaluation Criteria in Solid Tumors.
BACKGROUND:Patients with advanced soft tissue sarcomas (STS) have limited therapeutic options. Sorafenib (BAY 43-9006) is a multitargeted tyrosine kinase inhibitor of raf, vascular endothelial growth factor receptors 1 (VEGFR1) through 3, platelet-derived growth factor B, fms-like tyrosine kinase 3, and c-kit, and some of these may be relevant in STS. METHODS: The authors tested sorafenib at a dose of 400 mg twice daily in patients with advanced vascular sarcoma (VS), high-grade liposarcomas, and leiomyosarcomas who had received 0 or 1 previous regimens for advanced disease. RESULTS: Fifty-one patients were accrued to the study, and 37 were evaluable for toxicity and response. There were no unexpected side effects and no confirmed responses. The median progression-free survival was 3 months, and the median overall survival was 17 months. Six of 8 patients in the VS cohort had prolonged clinical benefit (stable disease or better), resulting in a median progression-free survival of 5 months compared with 2 to 3 months for the patients who had liposarcoma and leiomyosarcomas. CONCLUSIONS:Sorafenib at the dose and schedule studied did not result in any responses in the VS, liposarcoma, or leiomyosarcoma cohort according to Response Evaluation Criteria in Solid Tumors.
Authors: P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther Journal: J Natl Cancer Inst Date: 2000-02-02 Impact factor: 13.506
Authors: Ralf Erber; Andreas Thurnher; Alice D Katsen; Gesine Groth; Heinz Kerger; Hans-Peter Hammes; Michael D Menger; Axel Ullrich; Peter Vajkoczy Journal: FASEB J Date: 2003-12-04 Impact factor: 5.191
Authors: Sandra P D'Angelo; Rodrigo R Munhoz; Deborah Kuk; Johnathan Landa; Eliza W Hartley; Michael Bonafede; Mark A Dickson; Mrinal Gounder; Mary L Keohan; Aimee M Crago; Cristina R Antonescu; William D Tap Journal: Oncology Date: 2015-06-03 Impact factor: 2.935
Authors: Jason R Hasenstein; Kelsey Kasmerchak; Darya Buehler; Gholam Reza Hafez; Kevin Cleary; John S Moody; Kevin R Kozak Journal: Neoplasia Date: 2012-02 Impact factor: 5.715
Authors: T Valentin; C Fournier; N Penel; E Bompas; L Chaigneau; N Isambert; C Chevreau Journal: Invest New Drugs Date: 2013-09-05 Impact factor: 3.850
Authors: Kathleen B Smith; Linh M Tran; Brenna M Tam; Elizabeth M Shurell; Yunfeng Li; Daniel Braas; William D Tap; Heather R Christofk; Sarah M Dry; Fritz C Eilber; Hong Wu Journal: Am J Pathol Date: 2013-02-12 Impact factor: 4.307
Authors: Lionel Mignion; Prasanta Dutta; Gary V Martinez; Parastou Foroutan; Robert J Gillies; Bénédicte F Jordan Journal: Cancer Res Date: 2013-11-27 Impact factor: 12.701
Authors: Robert J Canter; Dariusz Borys; Abimbola Olusanya; Chin-Shang Li; Li-Yuan Lee; Robert D Boutin; Scott D Christensen; Robert M Tamurian; Arta M Monjazeb Journal: Ann Surg Oncol Date: 2014-02-20 Impact factor: 5.344
Authors: Martina Zacher; Markus V Heppt; Titus J Brinker; Kinan M Hayani; Michael J Flaig; Carola Berking Journal: Med Oncol Date: 2018-08-23 Impact factor: 3.064
Authors: Darya Buehler; Stephanie R Rice; John S Moody; Patrick Rush; Gholam-Reza Hafez; Steven Attia; B Jack Longley; Kevin R Kozak Journal: Am J Clin Oncol Date: 2014-10 Impact factor: 2.339